In NAFLD/NASH, whether deregulation of specific S100 proteins expression/activity in specific hepatic cells, i.e., hepatocytes versus other non-parenchymal cells, could predict progression to severe stages such as cirrhosis, or risk of cancer development, is still a key question, but available data for example on S100A11 clearly suggest that it could be the case [65]. This evidence concerns the gene S100A1 and metabolic dysfunction-associated steatotic liver disease.